
Jupiter Neurosciences fell 98.2% from $95.25 to $1.70, behind the S&P 500's +11.2%. Its worst day was May 20 (−36.7%), and its low came Nov 16 at $1.70.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Jupiter Neurosciences closed at its highest level of the year, 2.4% above where the year started.
+4.0% · S&P 500 +0.4%
Jupiter Neurosciences shares fell 23.5%, while the S&P 500 fell 0.0%.
Story events cover the past 12 months · Times ET
−23.5% · S&P 500 0.0%
EPS of $-5.25 missed the $-4.50 estimate on $21,796.00 revenue (est. $107,000.00).
−2.9% · S&P 500 +0.1%
EPS of $-4.50 missed the $-3.75 estimate on $18,652.00 revenue (est. $186,000.00).
−3.3% · S&P 500 −1.2%
Jupiter Neurosciences shares rose 20.7%, while the S&P 500 rose 0.6%.
+20.7% · S&P 500 +0.6%
T TO COMPLETION, DATED JUNE 26, 2026 Jupiter Neurosciences, Inc.
−25.0% · S&P 500 +1.6%
Jupiter Neurosciences shares fell 20.9%, while the S&P 500 rose 0.1%.
−20.9% · S&P 500 +0.1%
Jupiter Neurosciences shares fell 25.7%, while the S&P 500 fell 0.2%.
−25.7% · S&P 500 −0.2%
EPS of $-4.08 missed the $-3.75 estimate on $24,245.00 revenue (est. $400,000.00).
−12.7% · S&P 500 −0.2%
Where it ended: a close of $1.70 on Nov 16, 2026.
Nothing in the past 12 months.
All JUNS analyst actionsNothing in the past 12 months.
All JUNS dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for JUNS and SPY from Benzinga historical bars. Not investment advice.